BERLIN, Dec. 7, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that Jerini Ophthalmic, Inc., its wholly-owned U.S. subsidiary, signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of AMD (age-related macular degeneration). The collaboration will explore the novel signaling pathways targeted by two of Jerini Ophthalmic’s leading drug candidates: JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of the complement cascade. Under the terms of the agreement, Jerini Ophthalmic will finance full-time equivalents (FTE) and research costs over three years at the UCL Institute of Ophthalmology and has certain exclusive rights over the intellectual property generated through the collaboration.
